$AWH
Aspira Women's Health Inc.

2020 Q4 Form 10-Q Financial Statement

#000092661720000079 Filed on November 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $1.450M $1.239M $1.285M
YoY Change 10.69% -3.58% 66.02%
Cost Of Revenue $1.220M $807.0K $949.0K
YoY Change 54.43% -14.96% 21.98%
Gross Profit $230.0K $432.0K $336.0K
YoY Change -55.77% 28.57% -8500.0%
Gross Profit Margin 15.86% 34.87% 26.15%
Selling, General & Admin $5.570M $4.118M $3.846M
YoY Change 51.36% 7.07% 53.23%
% of Gross Profit 2421.74% 953.24% 1144.64%
Research & Development $730.0K $595.0K $340.0K
YoY Change 204.17% 75.0% 163.57%
% of Gross Profit 317.39% 137.73% 101.19%
Depreciation & Amortization $90.00K $70.00K $60.00K
YoY Change 80.0% 16.67% -62.5%
% of Gross Profit 39.13% 16.2% 17.86%
Operating Expenses $6.300M $4.713M $4.186M
YoY Change 60.71% 12.59% 58.62%
Operating Profit -$6.070M -$4.281M -$3.850M
YoY Change 78.53% 11.19% 45.67%
Interest Expense $0.00 $10.00K $30.00K
YoY Change -100.0% -66.67% -400.0%
% of Operating Profit
Other Income/Expense, Net $0.00 -$11.00K -$4.000K
YoY Change 175.0% 33.33%
Pretax Income -$6.080M -$4.290M -$3.820M
YoY Change 79.35% 12.3% 44.15%
Income Tax
% Of Pretax Income
Net Earnings -$6.080M -$4.287M -$3.820M
YoY Change 79.35% 12.23% 44.04%
Net Earnings / Revenue -419.31% -346.0% -297.28%
Basic Earnings Per Share
Diluted Earnings Per Share -$58.33K -$41.57K -$39.32K
COMMON SHARES
Basic Shares Outstanding 104.1M 103.8M 97.19M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.60M $18.80M $14.60M
YoY Change 41.88% 28.77% 23.73%
Cash & Equivalents $16.63M $18.84M $14.64M
Short-Term Investments
Other Short-Term Assets $1.100M $500.0K $400.0K
YoY Change 37.5% 25.0% 100.0%
Inventory $30.00K $0.00 $29.00K
Prepaid Expenses
Receivables $865.0K $848.0K $996.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $18.60M $20.25M $16.05M
YoY Change 38.72% 26.17% 25.39%
LONG-TERM ASSETS
Property, Plant & Equipment $583.0K $1.000M $399.0K
YoY Change 65.16% 150.63% -43.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $13.00K $0.00 $84.00K
YoY Change 0.0% -100.0%
Total Long-Term Assets $1.002M $1.014M $483.0K
YoY Change 139.71% 109.94% -31.0%
TOTAL ASSETS
Total Short-Term Assets $18.60M $20.25M $16.05M
Total Long-Term Assets $1.002M $1.014M $483.0K
Total Assets $19.61M $21.27M $16.53M
YoY Change 41.78% 28.62% 22.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.103M $1.315M $900.0K
YoY Change 29.01% 46.11% 80.0%
Accrued Expenses $3.618M $2.815M $2.403M
YoY Change 39.8% 17.15% 41.35%
Deferred Revenue
YoY Change
Short-Term Debt $611.0K $476.0K $200.0K
YoY Change 101.65% 138.0% 6.38%
Long-Term Debt Due $645.0K
YoY Change 234.2%
Total Short-Term Liabilities $6.000M $4.600M $3.537M
YoY Change 50.83% 30.05% 47.38%
LONG-TERM LIABILITIES
Long-Term Debt $3.477M $1.700M $1.148M
YoY Change 216.38% 48.08% -11.69%
Other Long-Term Liabilities $400.0K $400.0K $21.00K
YoY Change 2976.92% 1804.76%
Total Long-Term Liabilities $3.477M $2.100M $1.169M
YoY Change 212.68% 79.64% -10.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.000M $4.600M $3.537M
Total Long-Term Liabilities $3.477M $2.100M $1.169M
Total Liabilities $9.886M $6.700M $4.706M
YoY Change 94.22% 42.37% 25.03%
SHAREHOLDERS EQUITY
Retained Earnings -$440.1M -$434.0M -$418.8M
YoY Change 4.24% 3.63% 3.63%
Common Stock $105.0K $97.00K
YoY Change 8.25% 29.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.719M $14.55M $11.83M
YoY Change
Total Liabilities & Shareholders Equity $19.61M $21.30M $16.53M
YoY Change 41.78% 28.83% 22.7%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$6.080M -$4.287M -$3.820M
YoY Change 79.35% 12.23% 44.04%
Depreciation, Depletion And Amortization $90.00K $70.00K $60.00K
YoY Change 80.0% 16.67% -62.5%
Cash From Operating Activities -$4.750M -$3.070M -$3.440M
YoY Change 64.93% -10.76% 50.22%
INVESTING ACTIVITIES
Capital Expenditures -$220.0K -$150.0K -$40.00K
YoY Change 2100.0% 275.0% 33.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$220.0K -$150.0K -$40.00K
YoY Change 2100.0% 275.0% 33.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.770M 11.11M 1.940M
YoY Change -5640.0% 472.68% -3333.33%
NET CHANGE
Cash From Operating Activities -4.750M -3.070M -3.440M
Cash From Investing Activities -220.0K -150.0K -40.00K
Cash From Financing Activities 2.770M 11.11M 1.940M
Net Change In Cash -2.200M 7.890M -1.540M
YoY Change -25.17% -612.34% -35.29%
FREE CASH FLOW
Cash From Operating Activities -$4.750M -$3.070M -$3.440M
Capital Expenditures -$220.0K -$150.0K -$40.00K
Free Cash Flow -$4.530M -$2.920M -$3.400M
YoY Change 57.84% -14.12% 50.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
awh Net Changes In Accounts Payable Related To Capital Expenditures
NetChangesInAccountsPayableRelatedToCapitalExpenditures
154000
awh Net Increase In Right Of Use Assets
NetIncreaseInRightOfUseAssets
84000
awh Net Increase In Right Of Use Assets
NetIncreaseInRightOfUseAssets
369000
awh Percentage Of Royalty Paid
PercentageOfRoyaltyPaid
0.04
awh Proceeds From Issuance Of Common Stock In Conjunction With Exercise Of Underwriters Option To Purchase Additional Shares In Connection With Public Offering Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockInConjunctionWithExerciseOfUnderwritersOptionToPurchaseAdditionalSharesInConnectionWithPublicOfferingNetOfIssuanceCosts
2092000
awh Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
1005000
CY2020Q2 awh Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5060000
dei Amendment Flag
AmendmentFlag
false
dei City Area Code
CityAreaCode
512
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Document Type
DocumentType
10-Q
dei Entity Address Address Line1
EntityAddressAddressLine1
12117 Bee Caves Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Building Three
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78738
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Central Index Key
EntityCentralIndexKey
0000926617
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
104085827
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity File Number
EntityFileNumber
001-34810
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Registrant Name
EntityRegistrantName
Aspira Women's Health Inc.
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1158000
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
848000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
20251000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
448431000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2815000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
430802000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
107000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9795345
CY2019Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020Q3 us-gaap Assets
Assets
21265000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
104041493
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97286157
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
104041493
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
97000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2551000
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
949000
dei Entity Shell Company
EntityShellCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0595156
dei Local Phone Number
LocalPhoneNumber
519-0400
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Trading Symbol
TradingSymbol
AWH
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1315000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
924000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
13410000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9360000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14636000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11703000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18836000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5276000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7133000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2200000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
807000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
276000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
178000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-54000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4210000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1421000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5542000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1966000
us-gaap Gross Profit
GrossProfit
679000
CY2019Q3 us-gaap Gross Profit
GrossProfit
336000
us-gaap Gross Profit
GrossProfit
1005000
CY2020Q3 us-gaap Gross Profit
GrossProfit
432000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
507000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
230000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
210000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-76000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-63000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
20000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-173000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-249000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
39000
CY2019Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
34000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
14000
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5000
us-gaap Interest Paid Net
InterestPaidNet
31000
us-gaap Interest Paid Net
InterestPaidNet
27000
CY2019Q4 us-gaap Inventory Net
InventoryNet
25000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
576000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
63000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
187000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
116000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
106000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
95000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
9000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
145000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11907000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
52000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4281000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
431000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
39000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
422000
CY2019Q4 us-gaap Liabilities
Liabilities
5090000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13828000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15491000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17377000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-121000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-267000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10094000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9977000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3716000
us-gaap Net Income Loss
NetIncomeLoss
-11850000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-4314000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-3820000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3706000
us-gaap Net Income Loss
NetIncomeLoss
-11824000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-3831000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4287000
us-gaap Operating Expenses
OperatingExpenses
12553000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
4186000
us-gaap Operating Expenses
OperatingExpenses
12912000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
4713000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11874000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3850000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
421000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
10000
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0939
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y8M12D
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
69000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
7152000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
3637000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
11827000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
774000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
340000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1370000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
595000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-422161000
us-gaap Revenues
Revenues
3205000
CY2020Q3 us-gaap Revenues
Revenues
1239000
us-gaap Royalty Expense
RoyaltyExpense
125000
us-gaap Royalty Expense
RoyaltyExpense
124000
us-gaap Payments For Royalties
PaymentsForRoyalties
57500
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
121000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
267000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
758000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13523000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
10652000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
804000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5059000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
353000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
141000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
143000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-433985000
us-gaap Revenues
Revenues
3230000
CY2019Q3 us-gaap Revenues
Revenues
1285000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7569000
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2425000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6000000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2152000
us-gaap Share Based Compensation
ShareBasedCompensation
893000
us-gaap Share Based Compensation
ShareBasedCompensation
1121000
CY2020Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
476000
CY2019Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
181000
CY2019Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
290000
CY2020Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
269000
CY2020Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
320000
CY2020Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
349000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
8738000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
7267000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13630000
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2092000
CY2020Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
10652000
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
3000
CY2019Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
62000
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
121000
CY2020Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
61000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
295000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
508000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83017019
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
97144586
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
99555194
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
103200612

Files In Submission

Name View Source Status
0000926617-20-000079-index-headers.html Edgar Link pending
0000926617-20-000079-index.html Edgar Link pending
0000926617-20-000079.txt Edgar Link pending
0000926617-20-000079-xbrl.zip Edgar Link pending
awh-20200930.xml Edgar Link completed
awh-20200930.xsd Edgar Link pending
awh-20200930x10q.htm Edgar Link pending
awh-20200930xex31_1.htm Edgar Link pending
awh-20200930xex31_2.htm Edgar Link pending
awh-20200930xex32_1.htm Edgar Link pending
awh-20200930_cal.xml Edgar Link unprocessable
awh-20200930_def.xml Edgar Link unprocessable
awh-20200930_lab.xml Edgar Link unprocessable
awh-20200930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending